Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3307077 | 0.84 | ALDH1A1 (0.53) | KMT2AALDH1A1LMNAMEN1TSHR | |
| SCHEMBL4971452 | 0.83 | ALDH1A1 (0.51) | KMT2AALDH1A1LMNAMEN1TSHR | |
| SCHEMBL1819794 | 0.78 | LMNA (0.97) | KMT2AALDH1A1LMNAMEN1TSHR | |
| SCHEMBL2789416 | 0.78 | LMNA (0.97) | KMT2AALDH1A1LMNAMEN1TSHR | |
| Hydrochloric Acid SCHEMBL5606289 | 0.77 | LMNA (1.00) | KMT2AALDH1A1LMNAMEN1TSHR | |
| SCHEMBL7657250 | 0.76 | LMNA (0.94) | KMT2AALDH1A1LMNAMEN1TSHR | |
| Mandelic Acid, Methyl Ester SCHEMBL29214409 | 0.72 | KMT2A (0.60) | KMT2AALDH1A1LMNAMEN1SMN1; SMN2 | |
| SCHEMBL11844280 | 0.72 | TDP1 (0.54) | KMT2AALDH1A1LMNAMEN1TSHR | |
| SCHEMBL4559889 | 0.72 | ALDH1A1 (0.50) | KMT2AALDH1A1LMNAMEN1TSHR | |
| SCHEMBL1683002 | 0.72 | RAB9A (0.58) | KMT2AALDH1A1LMNAMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099880-A1 | Alternate Process for Remifentanil Preparation | MALLINCKRODT INC. | 2010-04-22 | — | — | US | disclosed |
| EP-2081899-A2 | ALTERNATE PROCESS FOR REMIFENTANIL PREPARATION | Mallinckrodt Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080312448-A1 | Process for Synthesizing Remifentanil | MALLINCKRODT INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1984336-A2 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT, INC. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008045192-A2 | ALTERNATE PROCESS FOR REMIFENTANIL PREPARATION | MALLINCKRODT INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007087164-A2 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099880-A1 | Alternate Process for Remifentanil Preparation | OPRK1, OPRM1, OGFR | KMT2A 694/4885ALDH1A1 916/4885LMNA 3914/4885 |
| US-20080312448-A1 | Process for Synthesizing Remifentanil | OPRM1, OPRK1, OPRD1 | KMT2A 148/4885ALDH1A1 549/4885LMNA 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.